Related Experiment Video
Updated: Apr 14, 2026
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Therapeutic potential of targeting protein for Xklp2 silencing for pancreatic cancer
Tomohiro Miwa1, Toshio Kokuryo1, Yukihiro Yokoyama1
1Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.
Abstract:
The targeting protein for Xklp2 (TPX2) is a microtubule- and, cell cycle-associated protein who's overexpression has been reported in various malignancies. In this study, we verified the overexpression of TPX2 in both surgically resected specimens of pancreatic cancer and multiple pancreatic cancer cell lines. Subsequently, we found that TPX2 siRNA effectively suppressed the proliferation of pancreatic cancer cells in culture, and the direct injection of TPX2 siRNA into subcutaneously implanted pancreatic cancer cells in nude mice revealed antiproliferative effects. These results implied a therapeutic potential of TPX2 siRNA in pancreatic cancer. Among 56 angiogenesis-related factors examined using angiogenesis arrays, the average protein levels of insulin-like growth factor-binding protein-3 (IGFBP-3) were significantly higher in TPX2 siRNA-treated tumors than in the Control siRNA-treated tumors. Moreover, we demonstrated that CD34-positive microvessels were significantly reduced in tumors treated with TPX2 siRNA compared to tumors that treated with Control siRNA. The attenuated expression of CD34 in TPX2 siRNA-treated tumors coincided with the overexpression of IGFBP-3. These results indicated that TPX2 has an impact on tumor angiogenesis in pancreatic cancer. The results also implied that the antiangiogenic effect observed in TPX2 siRNA-treated pancreatic cancer cells may be partly explained by the upregulation of IGFBP-3.
Insights
Targeting protein for Xklp2 (TPX2) is overexpressed in pancreatic cancer. TPX2 siRNA suppressed tumor growth and reduced angiogenesis, suggesting its therapeutic potential in pancreatic cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Targeting protein for Xklp2 (TPX2) is a cell cycle-associated protein implicated in various malignancies.
- TPX2 overexpression is observed in pancreatic cancer tissues and cell lines.
Purpose of the Study:
- To investigate the role of TPX2 in pancreatic cancer proliferation and angiogenesis.
- To evaluate the therapeutic potential of TPX2 siRNA in pancreatic cancer models.
Main Methods:
- TPX2 expression was verified in pancreatic cancer specimens and cell lines.
- TPX2 siRNA was used to assess antiproliferative effects in vitro and in vivo.
- Angiogenesis arrays were employed to analyze angiogenesis-related factors, including IGFBP-3 and CD34 expression.
Main Results:
- TPX2 siRNA significantly suppressed pancreatic cancer cell proliferation in vitro and in vivo.
- TPX2 siRNA treatment led to increased levels of insulin-like growth factor-binding protein-3 (IGFBP-3).
- Tumor angiogenesis, indicated by reduced CD34-positive microvessels, was attenuated in TPX2 siRNA-treated tumors.
Conclusions:
- TPX2 plays a role in pancreatic cancer proliferation and tumor angiogenesis.
- TPX2 siRNA demonstrates therapeutic potential for pancreatic cancer by inhibiting proliferation and angiogenesis.
- The antiangiogenic effect of TPX2 siRNA may be mediated by the upregulation of IGFBP-3.
More Related Videos
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
